- Home
- PIII vs PMN Comparison
PIII vs PMN Comparison
Compare PIII & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | PMN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 23.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | PMN |
|---|---|---|
| Price | $3.53 | $8.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.25 | ★ $72.67 |
| AVG Volume (30 Days) | 11.2K | ★ 33.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $6.27 |
| 52 Week High | $14.50 | $39.75 |
Technical Indicators
Market Signals| Indicator | PIII | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 21.99 | 70.11 |
| Support Level | $3.50 | $8.31 |
| Resistance Level | $5.20 | $9.15 |
| Average True Range (ATR) | 0.23 | 0.56 |
| MACD | -0.05 | -0.22 |
| Stochastic Oscillator | 13.21 | 37.68 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.